WIDE MOAT STOCKS COMPARISON

Checking

 

Stock Comparison

Abbott Laboratories vs Thermo Fisher Scientific Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Abbott Laboratories

ABT · New York Stock Exchange

Market cap (USD)$173.2B
Gross margin (TTM)52.5%
Operating margin (TTM)15.8%
Net margin (TTM)11.6%
SectorHealthcare
IndustryMedical devices
CountryUS
Data as of2026-08-23
22/100
Moat score

Weighted across the company's segments.

Full stock profile

Dive deeper into Abbott Laboratories's moat claims, evidence, and risks.

View ABT analysis

Thermo Fisher Scientific Inc.

TMO · New York Stock Exchange

Market cap (USD)$242.8B
Gross margin (TTM)40.8%
Operating margin (TTM)17.6%
Net margin (TTM)15%
SectorHealthcare
IndustryDiagnostics and life science tools
CountryUS
Data as of2026-08-23
59/100
Moat score

Weighted across the company's segments.

Full stock profile

Dive deeper into Thermo Fisher Scientific Inc.'s moat claims, evidence, and risks.

View TMO analysis

Comparison highlights

  • Moat score gap: Thermo Fisher Scientific Inc. leads (59 / 100 vs 22 / 100 for Abbott Laboratories).
  • Segment focus: Abbott Laboratories has 9 segments (27% in Cardiovascular and Electrophysiology Devices); Thermo Fisher Scientific Inc. has 4 segments (53.5% in Laboratory Products and Biopharma Services).
  • Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs Moderate.
  • Moat breadth: Abbott Laboratories has 1 moat types across 1 domains; Thermo Fisher Scientific Inc. has 3 across 2.

Primary market context

Abbott Laboratories

Cardiovascular and Electrophysiology Devices

Market

Rhythm management, electrophysiology, heart failure, vascular and structural-heart devices

Geography

Global

Customer

Hospitals, ambulatory surgery centers and cardiovascular clinicians

Role

Implantable and procedure-based device manufacturer

Revenue share

27%

Thermo Fisher Scientific Inc.

Laboratory Products and Biopharma Services

Market

Laboratory supplies distribution/market channel plus outsourced biopharma services (CDMO/CRO)

Geography

Global

Customer

Pharma & biotech; academic/government labs; industrial and clinical laboratories

Role

Distributor/market channel and outsourced services provider

Revenue share

53.5%

Side-by-side metrics

Abbott Laboratories
Thermo Fisher Scientific Inc.
Ticker / Exchange
ABT - New York Stock Exchange
TMO - New York Stock Exchange
Market cap (USD)
$173.2B
$242.8B
Gross margin (TTM)
52.5%
40.8%
Operating margin (TTM)
15.8%
17.6%
Net margin (TTM)
11.6%
15%
Sector
Healthcare
Healthcare
Industry
Medical devices
Diagnostics and life science tools
HQ country
US
US
Primary segment
Cardiovascular and Electrophysiology Devices
Laboratory Products and Biopharma Services
Market structure
Oligopoly
Competitive
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
22 / 100
59 / 100
Moat domains
Demand
Demand, Supply
Last update
2026-09-05
2026-09-05

Moat coverage

Shared moat types

Installed Base Consumables

Abbott Laboratories strengths

No unique moat types yet.

Thermo Fisher Scientific Inc. strengths

Distribution ControlProcurement Inertia

Segment mix

Abbott Laboratories segments

Full profile >

Established Pharmaceutical Products

Competitive

11.9%

Pediatric Nutrition

Oligopoly

8.1%

Adult Nutrition

Oligopoly

8.9%

Core Laboratory Diagnostics

Oligopoly

11.3%

Rapid and Molecular Diagnostics

Competitive

6%

Cancer Diagnostics

Competitive

7.3%

Diabetes Care (CGM and glucose monitoring)

Oligopoly

17.4%

Cardiovascular and Electrophysiology Devices

Oligopoly

27%

Neuromodulation Devices

Oligopoly

2.1%

Thermo Fisher Scientific Inc. segments

Full profile >

Life Sciences Solutions

Oligopoly

19.7%

Analytical Instruments

Oligopoly

16.5%

Specialty Diagnostics

Oligopoly

10.3%

Laboratory Products and Biopharma Services

Competitive

53.5%

Act on this comparison

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.